Frank Baas

Frank Baas

Company: Complement Pharma

Job title: Chief Scientific Officer


Terminal Pathway Inhibitors for Neurodegenerative Disorders 3:00 pm

Terminal pathway inhibition facilitates regeneration CP010, a humanized C6 antibody, is an effective C6 blocker in vivo Systemic administration of CP010 prevents relapse in experimental autoimmune encephalomyelitis Download the event guide here for full session detailsRead more

day: Track B - Day 1 PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.